var data={"title":"NSAIDs (including aspirin): Treatment of gastroduodenal toxicity","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">NSAIDs (including aspirin): Treatment of gastroduodenal toxicity</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/contributors\" class=\"contributor contributor_credentials\">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/contributors\" class=\"contributor contributor_credentials\">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 09, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1105304413\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nonsteroidal antiinflammatory drugs (NSAIDs), including <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, cause considerable morbidity and mortality related to gastric and duodenal ulcer disease, particularly by causing gastrointestinal (GI) bleeding. NSAIDs are also important causes of GI bleeding in children [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>The treatment of gastroduodenal toxicity associated with NSAID therapy will be reviewed here. Modalities used for primary and secondary prevention of gastroduodenal toxicity, including the role of cyclooxygenase (COX)-2 selective NSAIDs, are discussed separately as is the pathogenesis of the gastroduodenal toxicity. The prevention of recurrent gastroduodenal toxicity is also discussed separately. (See <a href=\"topic.htm?path=nsaids-including-aspirin-pathogenesis-of-gastroduodenal-toxicity\" class=\"medical medical_review\">&quot;NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity&quot;</a> and <a href=\"topic.htm?path=nsaids-including-aspirin-primary-prevention-of-gastroduodenal-toxicity\" class=\"medical medical_review\">&quot;NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity&quot;</a> and <a href=\"topic.htm?path=nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity\" class=\"medical medical_review\">&quot;NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2806727726\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If a patient develops an ulcer while on a nonsteroidal antiinflammatory drug (NSAID) or <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, the NSAID or aspirin should be stopped if at all possible and traditional ulcer therapy with a proton pump inhibitor or an H2 antagonist started. Proton pump inhibitors are preferred because they are associated with superior ulcer healing [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/2-4\" class=\"abstract_t\">2-4</a>]. (See <a href=\"topic.htm?path=peptic-ulcer-disease-management\" class=\"medical medical_review\">&quot;Peptic ulcer disease: Management&quot;</a>.) If the patient has been taking low-dose aspirin for cardiovascular prophylaxis, there is no consensus as to when to resume the aspirin. The indication for the low-dose aspirin should be reviewed and the severity of the ulcer presentation considered. For most patients, the author recommends low-dose aspirin, if still indicated, be restarted one to two weeks after initiating therapy with a proton pump inhibitor.</p><p>As in all patients with peptic ulcers, the patient's H. pylori status should also be assessed (if not done previously) [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/5\" class=\"abstract_t\">5</a>]; if positive, appropriate therapy for H. pylori should be instituted [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/6\" class=\"abstract_t\">6</a>]. However, the sensitivity of H. pylori testing in the setting of acute GI bleeding is significantly reduced. (See <a href=\"topic.htm?path=treatment-regimens-for-helicobacter-pylori\" class=\"medical medical_review\">&quot;Treatment regimens for Helicobacter pylori&quot;</a> and <a href=\"topic.htm?path=peptic-ulcer-disease-management#H527229648\" class=\"medical medical_review\">&quot;Peptic ulcer disease: Management&quot;, section on 'Eradication of Helicobacter pylori'</a> and <a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection#H1153255898\" class=\"medical medical_review\">&quot;Indications and diagnostic tests for Helicobacter pylori infection&quot;, section on 'Patient undergoing upper endoscopy'</a>.)</p><p>For patients who must remain on low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or NSAID therapy, randomized trials have shown that ulcer healing occurs more rapidly with a proton pump inhibitor than an H2 antagonist [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/7,8\" class=\"abstract_t\">7,8</a>], <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/9\" class=\"abstract_t\">9</a>], or <a href=\"topic.htm?path=sucralfate-drug-information\" class=\"drug drug_general\">sucralfate</a> [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/10\" class=\"abstract_t\">10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one trial, 541 patients who had ulcers or numerous (&gt;10) erosions in either the stomach or duodenum and who required continuous treatment with NSAIDs were randomly assigned to treatment with <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">omeprazole</a> (20 or 40 mg PO daily) or the H2 antagonist <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">ranitidine</a> (150 mg PO twice daily) for four or eight weeks [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/7\" class=\"abstract_t\">7</a>]. At eight weeks, the success rate was greater with omeprazole (80 and 79 versus 63 percent with ranitidine).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a second trial, 353 patients with benign gastric ulcers who continued to receive stable doses of NSAIDs were randomly assigned to treatment with <a href=\"topic.htm?path=lansoprazole-drug-information\" class=\"drug drug_general\">lansoprazole</a> (15 or 30 mg PO daily) or <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">ranitidine</a> (150 mg PO twice daily) for eight weeks [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/8\" class=\"abstract_t\">8</a>]. Healing rates were higher in patients treated with lansoprazole as compared with ranitidine (69, 73, and 53 percent, respectively).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another trial, 935 patients who had ulcers or numerous (&gt;10) erosions in the stomach or duodenum (or both) and who required continuous treatment with NSAIDs were randomly assigned to treatment with <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">omeprazole</a> (20 or 40 mg PO daily) or <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> (200 mcg four times per day). Patients were treated for four weeks or, in the absence of ulcer healing, eight weeks [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/9\" class=\"abstract_t\">9</a>]. The rates of healing of gastric ulcers (87 versus 73 percent) and duodenal ulcers (93 versus 77 percent) were significantly higher with omeprazole (20 mg) than with misoprostol. The outcomes with 40 <span class=\"nowrap\">mg/day</span> of omeprazole were also superior to misoprostol.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The efficacy of <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">omeprazole</a> (20 mg daily) was compared to <a href=\"topic.htm?path=sucralfate-drug-information\" class=\"drug drug_general\">sucralfate</a> (2 g twice daily) in a much smaller study of 98 patients with gastric and duodenal ulcers who required continued treatment with NSAIDs [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/10\" class=\"abstract_t\">10</a>]. At eight weeks, omeprazole was significantly superior to sucralfate for healing gastric ulcers (87 versus 52 percent); the differences in the rates of healing of duodenal ulcers (95 versus 73 percent) did not reach statistical significance.</p><p/><p>There are no data that suggest that any of the available proton pump inhibitors are more efficacious than another. The table lists the available medications and their usual dose (<a href=\"image.htm?imageKey=GAST%2F81079\" class=\"graphic graphic_table graphicRef81079 \">table 1</a>). </p><p class=\"headingAnchor\" id=\"H2941017426\"><span class=\"h2\">Duration of PPI therapy and role of endoscopy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment with a PPI is generally continued for four to eight weeks, depending on the ulcer location (duodenal or gastric (<a href=\"image.htm?imageKey=GAST%2F81079\" class=\"graphic graphic_table graphicRef81079 \">table 1</a>)), the original ulcer size and the severity of the initial clinical presentation. Endoscopic follow-up to assess ulcer healing is usually unnecessary for duodenal ulcers, but should be performed to assess healing of gastric ulcers if there had been any concern that malignancy had not been excluded at the initial endoscopy.</p><p>Maintenance PPI therapy is indicated in patients who must remain on or resume low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or NSAID or treatment. (See <a href=\"topic.htm?path=nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity\" class=\"medical medical_review\">&quot;NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity&quot;</a>.) In the author&rsquo;s opinion, and those of others [<a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/11\" class=\"abstract_t\">11</a>], the proven benefits of PPI maintenance therapy for secondary prevention of NSAID- or low dose aspirin-associated ulcers considerably outweigh potential risks of long term PPI therapy.</p><p class=\"headingAnchor\" id=\"H3807247994\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who develop a symptomatic gastric or duodenal ulcer while on a nonsteroidal antiinflammatory drug (NSAID) <span class=\"nowrap\">and/or</span> low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, the author recommends stopping the NSAID <span class=\"nowrap\">and/or</span> aspirin. (See <a href=\"#H2806727726\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients in whom the NSAID <span class=\"nowrap\">and/or</span> low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> can be stopped, we recommend treating with a proton pump inhibitor for four to eight weeks (<a href=\"image.htm?imageKey=GAST%2F81079\" class=\"graphic graphic_table graphicRef81079 \">table 1</a>) (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H2806727726\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients in whom the NSAID or low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> cannot be stopped or must be restarted, we recommend treatment with a proton pump inhibitor (<a href=\"image.htm?imageKey=GAST%2F81079\" class=\"graphic graphic_table graphicRef81079 \">table 1</a>) (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). Maintenance therapy with a PPI is also warranted in such patients. (See <a href=\"topic.htm?path=peptic-ulcer-disease-management\" class=\"medical medical_review\">&quot;Peptic ulcer disease: Management&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The patient's H. pylori status should also be assessed; if positive, appropriate therapy should be instituted. (See <a href=\"topic.htm?path=treatment-regimens-for-helicobacter-pylori\" class=\"medical medical_review\">&quot;Treatment regimens for Helicobacter pylori&quot;</a> and <a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection#H1153255898\" class=\"medical medical_review\">&quot;Indications and diagnostic tests for Helicobacter pylori infection&quot;, section on 'Patient undergoing upper endoscopy'</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/1\" class=\"nounderline abstract_t\">Cardile S, Martinelli M, Barabino A, et al. Italian survey on non-steroidal anti-inflammatory drugs and gastrointestinal bleeding in children. World J Gastroenterol 2016; 22:1877.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/2\" class=\"nounderline abstract_t\">Mo C, Sun G, Lu ML, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21:5382.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/3\" class=\"nounderline abstract_t\">Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118:1894.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/4\" class=\"nounderline abstract_t\">Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol 2016; 51:177.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/5\" class=\"nounderline abstract_t\">Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol 2015; 110:684.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/6\" class=\"nounderline abstract_t\">Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151:51.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/7\" class=\"nounderline abstract_t\">Yeomans ND, Tulassay Z, Juh&aacute;sz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/8\" class=\"nounderline abstract_t\">Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000; 160:1455.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/9\" class=\"nounderline abstract_t\">Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338:727.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/10\" class=\"nounderline abstract_t\">Bianchi Porro G, Lazzaroni M, Manzionna G, Petrillo M. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 1998; 12:355.</a></li><li><a href=\"https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity/abstract/11\" class=\"nounderline abstract_t\">Laine L, Nagar A. Long-Term PPI Use: Balancing Potential Harms and Documented Benefits. Am J Gastroenterol 2016; 111:913.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 14 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3807247994\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1105304413\" id=\"outline-link-H1105304413\">INTRODUCTION</a></li><li><a href=\"#H2806727726\" id=\"outline-link-H2806727726\">TREATMENT</a><ul><li><a href=\"#H2941017426\" id=\"outline-link-H2941017426\">Duration of PPI therapy and role of endoscopy</a></li></ul></li><li><a href=\"#H3807247994\" id=\"outline-link-H3807247994\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/14|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/81079\" class=\"graphic graphic_table\">- Active and maintenance therapy of gastroduodenal ulcers</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection\" class=\"medical medical_review\">Indications and diagnostic tests for Helicobacter pylori infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-including-aspirin-pathogenesis-of-gastroduodenal-toxicity\" class=\"medical medical_review\">NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-including-aspirin-primary-prevention-of-gastroduodenal-toxicity\" class=\"medical medical_review\">NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity\" class=\"medical medical_review\">NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=peptic-ulcer-disease-management\" class=\"medical medical_review\">Peptic ulcer disease: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-regimens-for-helicobacter-pylori\" class=\"medical medical_review\">Treatment regimens for Helicobacter pylori</a></li></ul></div></div>","javascript":null}